Boston, MA | www.1up.health
1upHealth helps payers, providers, and digital health companies build an end-to-end FHIR data strategy that is enabled by best-in-class tools on a scalable, serverless, and secure platform.
Our team of seasoned healthcare investors provides strategic and often non-dilutive capital tailored to healthcare and pharma business timelines, whether to develop or launch new medicines, acquire assets, or provide growth capital to finance strategic initiatives.
We are passionate about forming long-term partnerships with companies creating new technologies to address our most pressing healthcare challenges and improve patient care. Our experienced life sciences and technology teams focus on collaborating to develop AI and software-related themes within the healthcare space.
We invest across the sector and have partnered with companies in drug development and marketing, devices and diagnostics, generics, pharma and healthcare business services, and contract research, development and manufacturing.
Healthcare IT and Software
Healthcare Data and AI
OTC, Consumer, Cosmeceuticals
Pharma Services, CROs, CDMOs, Life Science Tools
Pharmaceuticals and Biotechnology
HEALTHCARE and LIFE SCIENCES
Working with both private and public companies, our custom financing solutions include and often combine common equity, convertible preferred equity, redeemable preferred equity, or convertible debt.
We seek to work with companies about to commence commercial operations through to profitability with secured debt or debt-like financing. We can tailor terms and structure to reflect a company’s stage of growth.
Our team can work with companies on either passive royalty financings (company receives a passive third-party and typically non-dilutive royalty) or synthetic royalty financings (company creates royalty on its own product). Royalty financings can include traditional royalty purchases, structured royalty acquisitions (including annual or cumulative caps), or royalty-backed debt.
We can work directly with companies to help bring new products or therapies to the market. Our structures can help companies achieve their financial, accounting, and strategic aims all while retaining control of the development of their assets.
We have worked directly with healthcare funds to help fund the exit of assets at the end of fund life, acquire earnouts, or help fund incremental investments post-LP commitment period. We can transact at the fund or asset level.
Reproduced with permission from Bloomberg L.P.
We welcomed Jennifer Doudna, Ph.D., Nobel laureate and co-discoverer of CRISPR, as our Chief Science Advisor in February 2022. Dr. Doudna assists Sixth Street in our long-term efforts to identify, evaluate, and advance commercial development opportunities within the CRISPR and gene-editing ecosystem. She is also leading the build of our Scientific Advisory Board, which will advise our team as we continue to finance the development and commercialization of innovative therapeutics and invest in healthcare technology companies across all stages of growth.Learn More
AUM presented as of 9/30/22 and excludes (1) Opps I, which was invested as a series of commitments across multiple vehicles of a former affiliate investment adviser; and (2) assets and commitments of certain vehicles established by Sixth Street for the purpose of facilitating third party co-invest opportunities. Calculation of assets under management differs from the calculation of regulatory assets under management and may differ from the calculations of other investment managers.